| Literature DB >> 35806920 |
Serafín López Palmero1, Miguel Angel López Zúñiga2, Virginia Rodríguez Martínez1, Raul Reyes Parrilla3, Ana Maria Alguacil Muñoz4, Waldo Sánchez-Yebra Romera5, Patricia Martín Rico6, Inmaculada Poquet Catalá6, Carlos Jiménez Guardiola7, Alfonso Del Pozo Pérez7, Ruben Lobato Cano8, Ana Maria Lazo Torres9, Gines López Martínez1, Luis Felipe Díez García1, Tesifon Parrón Carreño10.
Abstract
BACKGROUND: In general, transthoracic echocardiography (TTE) is the first diagnostic test used for patients with bacteremia or candidemia and clinical signs of Infective Endocarditis (IE). Point-of-care ultrasound (POCUS) may be used in addition to physical examination for the detection of structural heart disease and valve abnormalities.Entities:
Keywords: bacteremia; candidemia; infective endocarditis; point-of-care ultrasound (POCUS)
Year: 2022 PMID: 35806920 PMCID: PMC9267352 DOI: 10.3390/jcm11133636
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Microbiology.
|
|
| HACEK group: |
| Microorganisms usually considered epithelial contaminants, isolation in three or four blood culture flasks: |
| Others: |
Figure 1Demonstration of the POCUS technique. (A). POCUS at the patient’s hospital bedside. (B). Vegetation on aortic valve. (C). Severe aortic regurgitation. (D). Splenic infarction. LA: left atrium. LV: left ventricle.
Characteristics of patients with bacteremia or candidemia.
| Patients | H.U.T. | H.U.J | H.U.To. | H.U.MS | H.U.VB | H.U.V.N. |
|
|---|---|---|---|---|---|---|---|
| Patients recruited, | 101 (39.2%) | 54 (20.9%) | 45 (17.4%) | 38 (14.7%) | 12 (4.7%) | 8 (3.8%) | 0.001 * |
| Age, years (mean) | 65.1 | 67.8 | 71.1 | 67.7 | 66.7 | 70.8 | 0.776 ** |
| Gender (female), | 38 (37.6%) | 20 (37%) | 12 (26.6%) | 17 (44.7%) | 4 (33.3%) | 3 (37.5%) | 0.683 * |
| Number of POCUS examinations/year performed by involved operators | 500 | 450 | 220 | 250 | 350 | 150 | <0.001 * |
| Clinical manifestations, | |||||||
| Fever | 93 (92.1%) | 53 (98.14%) | 45 (100%) | 38 (100%) | 12 (100%) | 8 (100%) | 0.074 * |
| Duration of the fever, days (mean) | 2.8 | 1.8 | 1.9 | 1.7 | 2.6 | 2.5 | 0.182 ** |
| Shivering | 64 (63.3%) | 36 (66.6%) | 32 (71.1%) | 14 (36.8%) | 7 (58.3%) | 6 (75%) | 0.024 * |
| Anorexia | 65 (64.3%) | 29 (53.7%) | 31 (68.8%) | 15 (39.5%) | 4 (%) | 4 (50%) | 0.026 * |
| Weight loss | 32 (31.7%) | 20 (37%) | 18 (40%) | 5 (13.1%) | 3 (33.3%) | 1 (12.5%) | 0.080 * |
| Dyspnoea | 31 (30.7%) | 22 (40.7%) | 17 (33.7%) | 11 (28.9%) | 6 (50%) | 3 (37.5%) | 0.611 * |
| Myalgia | 36 (35.6%) | 17 (31.5%) | 11 (22.4%) | 3 (7.9%) | 5 (41.6%) | 2 (25%) | 0.034 * |
| Night sweats | 34 (33.6%) | 16 (29.6%) | 14 (31.1%) | 4 (10.5%) | 3 (25%) | 3 (37.5%) | 0.163 * |
| Heart murmur | 33 (32.6%) | 13 (24%) | 16 (35.5%) | 10 (26.3%) | 5 (41.6%) | 3 (37.5%) | 0.705 * |
| Risk factors, | |||||||
| Prosthetic heart valve | 3 (2.9%) | 11 (20%) | 10 (22%) | 3 (7.9%) | 3 (25%) | 1 (12.5%) | 0.003 * |
| Congenital heart disease | 0 | 3 (5.5%) | 1 (2.2%) | 0 | 0 | 0 | 0.140 * |
| Permanent pacemaker | 8 (7.9%) | 3 (5.5%) | 9 (20%) | 1 (2.6%) | 2 (16.6%) | 0 | 0.048 * |
| ICD | 2 (1.9%) | 2 (3.7%) | 1 (2.2%) | 2 (5.2%) | 0 | 0 | 0.857 * |
| Charlson Index (mean) | 3.5 | 4.2 | 4.7 | 2.9 | 4.1 | 4.1 | 0.014 ** |
| Deficient oral hygiene | 49 (48.5%) | 11 (20.3%) | 23 (51.1%) | 4 (10.5%) | 6 (50%) | 1 (12.5%) | 0.001 * |
| Dental procedures | 2 (1.9%) | 2 (3.7%) | 3 (6.6%) | 2 (5.3%) | 0 | 0 | 0.682 * |
| Endoscopy | 14 (13.8%) | 4 (7.4%) | 4 (8.8%) | 4 (10.5%) | 1 (8.3%) | 1 (12.5%) | 0.864 * |
| Surgery | 24 (23.7%) | 6 (11.1%) | 2 (4.4%) | 5 (13.2%) | 1 (8.3%) | 1 (12.5%) | 0.049 * |
| Immunosuppression | 24 (23.8%) | 11 (20.4%) | 9 (20%) | 15 (39.5%) | 3 (25%) | 2 (25%) | 0.350 * |
| Diabetes mellitus | 39 (38.6%) | 17 (31.5%) | 18 (40%) | 12 (31.6%) | 4 (33.3%) | 5 (62.5%) | 0.582 * |
| Chronic kidney disease | 29 (28.7%) | 14 (25.9%) | 5 (11.1%) | 4 (10.5%) | 4 (33.3%) | 2 (25%) | 0.078 * |
| Microbiology, | |||||||
| MSSA | 25 (24.7%) | 15 (27.7%) | 12 (26.6%) | 7 (18.4%) | 3 (25%) | 2 (25%) | 0.948 * |
| MRSA | 5 (4.9%) | 2 (3.7%) | 5 (11.1%) | 9 (23.7%) | 2 (16.6%) | 1 (12.5%) | 0.012 * |
| CNS | 16 (5.9%) | 8 (14.8%) | 5 (11.1%) | 4 (10.5%) | 0 | 0 | 0.512 * |
| Viridans streptococci | 6 (5.9%) | 1 (1.8%) | 4 (8.8%) | 4 (10.5%) | 3 (25%) | 2 (25%) | 0.036 * |
| Other streptococci | 14 (13.8%) | 8 (14.8%) | 6 (13.3%) | 2 (5.3%) | 4 (33.3%) | 0 | 0.172 * |
| 14 (13.8%) | 14 (25.9%) | 9 (20%) | 2 (5.3%) | 0 | 0 | 0.031 * | |
| 19 (18.8%) | 3 (5.5%) | 1 (2.2%) | 8 (21.1%) | 0 | 2 (25%) | 0.009 * | |
| Other microorganisms | 2 (1.9%) | 3 (5.5%) | 3 (6.6%) | 2 (5.3%) | 0 | 1 (12.5%) | 0.534 * |
| Duration of POCUS examination and interpretation, minutes (mean) | 9:43 | 08:26 | 23:39 | 15:36 | 15:02 | 11:03 | 0.001 ** |
* Chi-squared; ** Kruskal-Wallis; ICD: Implantable Cardioverter–Defibrillator. MSSA: Methicillin-sensitive staphylococcus aureus. MRSA: Methicillin-resistant Staphylococcus aureus. CNS: Coagulase-negative staphylococcus. H.U.T.: Torrecárdenas University Hospital, Almería. H.U.J: Jaén University Hospital. H.U.To: Toledo University Hospital. H.U.MS: Marina Salud University Hospital, Denia. H.U.VB: Vega Baja University Hospital, Orihuela. H.U.V.N.: Virgen de las Nieves University Hospital, Granada.
Proportion of cases of IE caused by different microorganisms.
| Definite ( | Possible ( | Rejected ( | |
|---|---|---|---|
| MSSA | 13 | 2 | 49 |
| MRSA | 3 | 2 | 19 |
| CNS | 10 | 1 | 22 |
| Viridans streptococcus | 8 | 1 | 11 |
| Other streptococcus | 11 | 1 | 22 |
| 13 | 1 | 25 | |
| 0 | 1 | 32 | |
| Other microorganisms | 6 | 9 | 5 |
| Total, | 64 (24.8%) | 9 (3.5%) | 185 (71.7%) |
MSSA: Methicillin-sensitive staphylococcus aureus. MRSA: Methicillin-resistant Staphylococcus aureus. CNS: Coagulase-negative staphylococcus.
Characteristics of IE cases (Definite and Possible).
| Patients ( | 73 |
|---|---|
| Location, | |
| Aortic | 33 (45.2%) |
| Mitral | 30 (41.1%) |
| Tricuspid | 5 (6.8%) |
| Aortic + mitral | 2 (2.7%) |
| Pacemaker lead/ICD | 3 (4.1%) |
| Type of valve, | |
| Native | 50 (68.5%) |
| Prosthetic | 20 (27.4%) |
| Pacemaker lead/ICD | 3 (4.1%) |
| Acquisition, | |
| Community | 45 (61.6%) |
| Healthcare-related | 28 (38.4%) |
| Heart surgery, | |
| Scheduled | 16 (76.2%) |
| Urgent | 5 (23.8%) |
| Indication for heart surgery, | |
| Heart failure | 7 (33.3%) |
| Uncontrolled infection | 11 (5.,4%) |
| Prevent septic embolism | 3 (14.3%) |
Usefulness of POCUS for the detection of signs suggestive of IE in patients with bacteremia or candidemia.
| TP | FP | FN | TN | Sensitivity | Specificity | PPV | NPV | Concordance (Kappa) | |
|---|---|---|---|---|---|---|---|---|---|
| Valvular vegetation | 52 | 11 | 15 | 180 | 0.77 | 0.94 | 0.82 | 0.92 | 0.733 |
| (0.67–0.87) | (0.90–0.97) | (0.61–0.92) | (0.88–0.96) | ||||||
| Aortic valve vegetation | 17 | 4 | 11 | 226 | 0.61 | 0.98 | 0.81 | 0.95 | 0.662 |
| (0.43–0.79) | (0.97–0.99) | (0.61–0.99) | (0.92–0.98) | ||||||
| Mitral valve vegetation | 30 | 5 | 5 | 218 | 0.86 | 0.97 | 0.86 | 0.97 | 0.835 |
| (0.74–0.97) | (0.96–0.99) | (0.72–0.98) | (0.95–0.99) | ||||||
| Tricuspid valve vegetation | 5 | 3 | 5 | 245 | 0.5 | 0.99 | 0.62 | 0.98 | 0.540 |
| (0.19–0.81) | (0.97–1) | (0.22–0.99) | (0.96–0.99) | ||||||
| Aortic regurgitation * | 67 | 20 | 21 | 150 | 0.76 | 0.88 | 0.77 | 0.87 | 0.645 |
| (0.67–0.85) | (0.83–0.93) | (0.67–0.86) | (0.82–0.92) | ||||||
| Mitral regurgitation * | 91 | 20 | 28 | 119 | 0.76 | 0.85 | 0.82 | 0.81 | 0.624 |
| (0.69–0.84) | (0.79–0.91) | (0.74–0.89) | (0.74–0.87) | ||||||
| Tricuspid regurgitation * | 81 | 18 | 23 | 136 | 0.77 | 0.88 | 0.82 | 0.85 | 0.667 |
| (0.69–0.85) | (0.83–0.93) | (0.73–0.89) | (0.79–0.91) | ||||||
| LV systolic dysfunction | 22 | 5 | 5 | 226 | 0.81 | 0.98 | 0.81 | 0.98 | 0.793 |
| (0.66–0.96) | (0.95–0.99) | (0.65–0.98) | (0.96–0.99) | ||||||
| LV dilatation | 15 | 3 | 4 | 236 | 0.79 | 0.98 | 0.83 | 0.98 | 0.796 |
| (0.60–0.97) | (0.97–1) | (0.63–0.99) | (0.96–0.99) | ||||||
| LA dilatation | 92 | 14 | 18 | 134 | 0.84 | 0.90 | 0.86 | 0.88 | 0.745 |
| (0.76–0.90) | (0.85–0.95) | (0.80–0.94) | (0.83–0.94) | ||||||
| RA dilatation | 37 | 11 | 10 | 200 | 0.78 | 0.95 | 0.77 | 0.95 | 0.729 |
| (0.67–0.90) | (0.91–0.97) | (0.64–0.90) | (0.92–0.98) | ||||||
| RV dilatation | 17 | 8 | 4 | 229 | 0.81 | 0.96 | 0.68 | 0.98 | 0.714 |
| (0.64–0.97) | (0.97–0.99) | (0.47–0.88) | (0.96–0.99) | ||||||
| Pericardial effusion | 14 | 9 | 2 | 233 | 0.87 | 0.96 | 0.61 | 0.99 | 0.696 |
| (0.71–1) | (0.94–0.99) | (0.39–0.83) | (0.98–0.99) |
TP: True positive. FP: False positive. FN: False negative. TN: True negative. PPV: Positive predictive value. NPV: Negative predictive value. LV: Left ventricle. AI: Left atrium. RA: Right atrium. RV: Right ventricle. * More than mild valvular regurgitation
Usefulness of POCUS for the detection of hepatomegaly, splenomegaly and septic embolisms in patients with bacteremia or candidemia.
| TP | FP | FN | TN | Sensitivity | Specificity | PPV | NPV | Concordance (Kappa) | |
|---|---|---|---|---|---|---|---|---|---|
| Hepatomegaly | 12 | 7 | 1 | 166 | 0.92 | 0.96 | 0.63 | 0.99 | 0.727 |
| (0.77–1) | (0.93–0.99) | (0.39–0.87) | (0.98–1) | ||||||
| Splenomegaly | 11 | 3 | 1 | 171 | 0.92 | 0.98 | 0.78 | 0.99 | 0.935 |
| (0.76–1) | (0.96–1) | (0.53–1) | (0.98–1) | ||||||
| Hepatic infarction | 3 | 1 | 2 | 180 | 0.6 | 0.99 | 0.75 | 0.99 | 0.659 |
| (0.17–1) | (0.98–1) | (0.20–0.99) | (0.97–1) | ||||||
| Splenic infarction | 4 | 0 | 4 | 178 | 0.5 | 1 | 1 | 0.98 | 0.657 |
| (0.15–0.84) | (1–1) | (0.87–1) | (0.95–1) | ||||||
| Renal infarction | 0 | 1 | 5 | 180 | - | 0.99 | - | 0.97 | - |
| (0.98–1) | (0.94–0.99) |
TP: True positive. FP: False positive. FN: False negative. TN: True negative. PPV: Positive predictive value. NPV: Negative predictive value.